United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - dabigatran etexilate mesylate (unii: sc7nuw5iit) (dabigatran - unii:i0vm4m70gc) - dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. pediatric use information is approved for boehringer ingelheim pharmaceuticals, inc.’s pradaxa (dabigatran etexilate) capsules. however, due to boehringer ingelheim pharmaceuticals, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. dabigatran etexilate capsules are contraindicated in patients with: • active pathological bleeding [see warnings and precautions ( 5.2) and adverse reactions ( 6.1)] • history of a seri

Canada - English - Health Canada

teva canada limited - dabigatran etexilate (dabigatran etexilate mesilate) - capsule - 75mg - dabigatran etexilate (dabigatran etexilate mesilate) 75mg - direct thrombin inhibitors

Canada - English - Health Canada

teva canada limited - dabigatran etexilate (dabigatran etexilate mesilate) - capsule - 150mg - dabigatran etexilate (dabigatran etexilate mesilate) 150mg - direct thrombin inhibitors

Canada - English - Health Canada

apotex inc - dabigatran etexilate (dabigatran etexilate mesilate) - capsule - 75mg - dabigatran etexilate (dabigatran etexilate mesilate) 75mg - direct thrombin inhibitors

Canada - English - Health Canada

apotex inc - dabigatran etexilate (dabigatran etexilate mesilate) - capsule - 110mg - dabigatran etexilate (dabigatran etexilate mesilate) 110mg - direct thrombin inhibitors

Canada - English - Health Canada

apotex inc - dabigatran etexilate (dabigatran etexilate mesilate) - capsule - 150mg - dabigatran etexilate (dabigatran etexilate mesilate) 150mg - direct thrombin inhibitors

United States - English - NLM (National Library of Medicine)

ascend laboratories, llc - dabigatran etexilate mesylate (unii: sc7nuw5iit) (dabigatran - unii:i0vm4m70gc) - dabigatran etexilate capsules is indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. dabigatran etexilate capsules is indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days.  dabigatran etexilate capsules is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. dabigatran etexilate capsules is indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism, in adult patients who have undergone hip replacement surgery.  pediatric use information is approved for boehringer ingelheim pharmaceuticals, inc.’s pradaxa (dabigatran etexilate) capsules. however, due to boehringer ingelheim pharmaceuticals, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. dabigatran etexilate capsules is contraindic

United States - English - NLM (National Library of Medicine)

american health packaging - dabigatran etexilate mesylate (unii: sc7nuw5iit) (dabigatran - unii:i0vm4m70gc) - dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. pediatric use information is approved for boehringer ingelheim pharmaceuticals, inc.’s pradaxa (dabigatran etexilate) capsules. however, due to boehringer ingelheim pharmaceuticals, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. dabigatran etexilate capsules are contraindicated in patients with: - active pathological bleeding [see warnings and precautions (5.2) and adverse reactions (6.1)] - history of a serious hypersensitivity

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - dabigatran etexilate mesilate, quantity: 172.95 mg (equivalent: dabigatran etexilate, qty 150 mg) - capsule, hard - excipient ingredients: dimeticone 350; purified talc; hyprolose; purified water; indigo carmine; hypromellose; carrageenan; acacia; potassium chloride; titanium dioxide; tartaric acid; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; potassium hydroxide; iron oxide black - prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). (see section 4.2 dose and method of administration for details of treatment duration). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - dabigatran etexilate mesilate, quantity: 126.83 mg (equivalent: dabigatran etexilate, qty 110 mg) - capsule, hard - excipient ingredients: hyprolose; hypromellose; tartaric acid; dimeticone 350; potassium chloride; acacia; purified talc; titanium dioxide; carrageenan; indigo carmine; purified water; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). (see section 4.2 dose and method of administration for details of treatment duration). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.